Last week the FDA approved Italfarmaco’s givinostat (ITF2357) for Duchenne muscular dystrophy. Givinostat is a novel histone deacetylase (HDAC) inhibitor and was approved for DMD patients
Focus Biomolecules will be exhibiting at the annual meeting of American Association for Cancer Research (AACR) in San Diego, April 7 – 10. Stop by our
New DUB inhibitor: Deubiquitinating enzymes, or DUBs, are proteases that regulate ubiquitination dynamics. DUBs have become promising targets for drug discovery across diverse therapeutic areas. For
Journal Club: In the January issue of J. Cellular Physiology, Arasaki and Hayata from the Tokyo University of Science studied the mechanisms of nuclear localization of
Journal Club: In the February issue of Nature Cancer, CJ Bergin and coworkers from the University of Ottawa demonstrated that vanoxerine (GBR-12909), a well-known dopamine transporter
Focus will be exhibiting at the BPS Biophysical Society meeting, Feb 11 – 13, 2024, in Philadelphia. Stop by our booth #1008 and chat with our
Website Created by Advanta Advertising LLC.
